BHBlair Rose Hamilton

Blair Rose Hamilton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Blair Rose Hamilton has a total of 191 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The effects of gender affirming hormone treatment on transgender men’s musculoskeletal health: a systematic review and meta-analysis

    by Ke Hu, Andrew Brown, Stephanie Montagner-Moraes, Jatinder Singh, Laura Charlton, James Barrett, Blair R. Hamilton

    For transgender men (individuals assigned female at birth who identify as male), GAHT usually involves testosterone administration, which reduces distress and increases the quality of life in trans...


  • Open Access

    The Effects of Gender Affirming Hormone Treatment on Transgender Men’s Musculoskeletal Health: A Systematic Review and Meta-Analysis

    by Ke Hu, Andrew Brown, Stephanie Montagner-Moraes, Jatinder Singh, Laura Charlton, James Barrett, Blair R. Hamilton

    Background: A previous meta-analysis by Singh-Ospina et al. (2017) suggested that Gender affirming hormone treatment (GAHT) does not change transgender men’s bone mineral density (BMD) at any clinically relevant site; emerging studies and advances in synthesis methods necessitate an updated evaluation. The primary aim was to update the bone measures of Singh-Ospina et al. (2017), with the secondary aim to expand measures to how GAHT affects musculoskeletal health. Methods: A systematic review with meta-analysis was conducted using studies published in English up to 31 July 2024, identified through three electronic databases (PubMed, Embase, SportDiscus), and final cross-referencing in summer 2025. Primary outcomes were longitudinal changes in femoral neck (FN), lumbar spine (LS), and total hip (TH) bone mineral density (BMD). Secondary outcomes included body composition and muscle strength. Standardised effect sizes (Hedges’ g ) were pooled using the inverse heterogeneity (IVhet) model. Results: GAHT (4 ± 5 years) was not associated with significant longitudinal changes in FN, LS, or TH BMD. In contrast, substantial anabolic effects were observed, including increases in BMI ( g = 0.13), body mass ( g = 0.18), fat-free mass ( g = 0.59), and muscle strength ( g = 0.86). Heterogeneity was high for muscle strength, FN and TH BMD, limiting confidence in pooled estimates. Conversely, changes in LS BMD, BMI, body mass and fat-free mass demonstrated low heterogeneity and greater consistency across studies. Conclusion: Masculinising GAHT does not negatively affect clinically relevant BMD sites while reliably increasing lean mass and muscle strength; however, the evidence base remains methodologically weak and highly variable, particularly for FN and TH. The need for continued clinical monitoring of bone health and muscle function, alongside high-quality longitudinal research incorporating advanced imaging modalities such as HR-pQCT is emphasised. Strengthening the evidence base will be essential for clarifying long-term skeletal trajectories as transgender men age. PROSPERO registration: CRD42024573102

  • Harmful anachronism: World Athletics reinstates gene testing to participate in women’s competitions

    by Silvia Camporesi, Shane M Heffernan, Pascal Borry, Jensen Brehaut, Tim Cable, Jonathan Cooper, Luke Cox, Antoine Duval, Niall Fife, Sasha Gollish, et al.


  • Open Access

    Musculoskeletal Health in Ageing Transgender and Gender Diverse Women: A Pilot Study

    by Blair R. Hamilton, Nina Mitic, Charlotte E. Linscott, Ke Hu, Maaike Esselaar, Alex Ireland

    Introduction: Age-related declines in bone and muscle health contribute substantially to frailty, falls, and functional loss in older adults. Despite the established musculoskeletal effects of hormone therapy (HT) in younger transgender and gender diverse women (TGDW), data on ageing TGDW do not exist. TGDW ≥50 years receiving feminising HT exhibit an 80% higher fracture incidence than cisgender adults. This pilot study explored the practicality of community-based recruitment of TGDW receiving HT and provided the first characterisation of musculoskeletal health in this population. Methods: Cross-sectional pilot study recruited forty-eight TGDW aged ≥50 years undergoing feminising HT through two UK community festivals. Body composition (bioelectrical impedance analysis), bone quality (quantitative ultrasound of the radius and tibia), muscle strength and power (handgrip dynamometry, countermovement jump, and 5× sit-to-stand test), and physical activity (IPAQ-SF)were analysed using descriptive statistics, one-sample t-tests against clinical thresholds, and regression models exploring associations between HT duration and musculoskeletal outcomes, adjusting for age, BMI, and physical activity level. Results: Sarcopenia incidence varied from 9% (handgrip strength) to 38% (countermovement jump power), and 38% of participants recorded counter-movement jump power below sarcopenia thresholds, whilst 21% could not complete the sit-to-stand test. Osteoporosis prevalence (8-13%) was higher than in the UK population (5%). Seventy-three per cent of participants were classified as overweight, and 33% classified as obese, higher than UK population norms (26%). Twenty-three per cent of TGDW were classed as physically active compared to their age-matched population (63%). Regression analyses showed no significant association between hormone therapy duration and musculoskeletal outcomes, whereas BMI (countermovement jump power β = 192.1, p adj =0.01; handgrip β = 0.60, p adj =0.02) was a stronger predictor of function. Conclusion: High sarcopenia and osteoporosis prevalence, elevated obesity, and low physical activity highlight areas of concern. Larger longitudinal studies to characterise musculoskeletal ageing using clinical measures are needed. WHAT IS ALREADY KNOWN ON THIS TOPIC: Ageing is associated with declines in bone and muscle health, leading to frailty, falls, and functional loss. Transgender and gender-diverse adults (TGDW) receiving feminising hormone therapy (HT) may experience musculoskeletal changes, but data on those aged ≥50 years are absent. WHAT THIS STUDY ADDS: Provides the first characterisation of musculoskeletal health in ageing TGDW, highlighting osteoporosis and sarcopenia prevalence, substantial variation in bone quality and muscle function, functional limitations in a subset, elevated BMI and reduced physical activity. Demonstrates the feasibility of multi-domain musculoskeletal assessment in this population and identifies BMI and physical activity as stronger determinants of function than hormone therapy duration. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY: Supports the need for larger longitudinal studies to track musculoskeletal ageing in TGDW. Highlights key modifiable risk factors (BMI, activity) for interventions, informing clinical management and health policy for older TGDW populations.


  • Open Access

    The effects of gender affirming hormone treatment on transgender women’s musculoskeletal health: A systematic review and meta-analysis

    by Andrew Brown, Stephanie Montagner-Moraes, Ke Hu, Jatinder Singh, Laura Charlton, James Barrett, Blair R. Hamilton


  • Open Access

    The Effects of Gender Affirming Hormone Treatment on Transgender Women’s Musculoskeletal Health: A Systematic Review and Meta-Analysis

    by Andrew Brown, Stephanie Montagner-Moraes, Jatinder Singh, Laura Charlton, James Barrett, Blair R. Hamilton

    Background: Gender-affirming hormone treatment (GAHT) aligns transgender women’s hormone profiles with their gender identity, alleviating gender dysphoria by inducing feminising changes. However, the effects of GAHT on musculoskeletal health, particularly bone mineral density (BMD), require ongoing evaluation. A previous meta-analysis showed GAHT had a small effect on lumbar spine (LS) BMD, but more recent studies and updated methodologies justify a new synthesis. Methods: A systematic review and meta-analysis were conducted using studies published in English up to 31/07/2024, identified via three electronic databases, cross-referencing, and expert review. Primary outcomes were changes in femoral neck (FN), LS, and total hip (TH) BMD. Secondary outcomes included changes in body composition. Standardised effect sizes (Hedges’ g) were pooled using the inverse heterogeneity (IVhet) model. Results: GAHT was associated with a significant increase in FN BMD (g = 0.13 [0.05, 0.20], p = 0.00). Significant gains were also observed in fat mass (FM) (g = 0.52), BMI (g = 0.16), and body fat percentage (BF%) (g = 0.79), while reductions were found in fat-free mass (FFM) (g = -0.21) and thigh muscle cross-sectional area (mCSA) (g = -1.02). Conclusion: GAHT maintains FN BMD in transgender women with increased FM and reduced fat-free mass. The heterogeneous nature of several outcomes and the absence of empirical data on ageing transgender women require further research and clinical monitoring of bone health (such as High-resolution peripheral quantitative computed tomography) and muscle health to clarify the long-term implications of GAHT, particularly as transgender women age.


  • Open Access

    Author’s response to “letter to the editor comment on: ‘A unique pseudo-eligibility analysis of longitudinal laboratory performance Data from a transgender female competitive cyclist’” by Lundberg, O’Connor, Kirk, Pollock, and Brown

    by Blair R. Hamilton, Ke Hu, Fergus Guppy, Yannis Pitsiladis

    Article Author’s response to “letter to the editor comment on: ‘A unique pseudo-eligibility analysis of longitudinal laboratory performance Data from a transgender female competitive cyclist’” by Lundberg, O’Connor, Kirk, Pollock, and Brown was published on November 28, 2024 in the journal Translational Exercise Biomedicine (volume 0, issue 0).

  • Open Access

    Effects of Gender-Affirming Hormone Treatment on Transgender Musculoskeletal Health

    by Andrew Brown, Stephanie Moraes, Blair Hamilton

    Gender-affirming hormone treatment (GAHT) is an intervention aimed at aligning transgender individuals' hormone levels with their gender identity, thereby alleviating gender dysphoria through modifications to secondary sex characteristics. However, to effectively promote skeletal health, it is crucial to consider the potential adverse effects of GAHT. A previous meta-analysis observed no significant effect of GAHT femoral neck (FN), lumbar spine (LS) or total hip (TH) bone mineral density (BMD) in transgender women. In transgender men, LS BMD showed a significant benefit (ES: 0.04 – 0.06 g•cm-2). However, since that analysis more data have been published and updated methods of meta-analysis have been developed; therefore, an updated systematic review and meta-analysis are warranted. Methods and analysis: Literature published in English up to 31/07/24 will be retrieved by searching 3 electronic databases, cross-referencing and expert review. The primary outcome measures will be changes in FN and LS BMD and lower limb BMD. The risk of bias for each study will be assessed using the Cochrane Risk of Bias instrument for non-randomised control trials (ROBINS-I), while the strength of evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) instrument. Standardised effect sizes will be calculated from each study and pooled using the inverse heterogeneity (IVhet) model. Prospero Trial Registration number: [CRD42024573102].


  • Open Access

    A unique pseudo-eligibility analysis of longitudinal laboratory performance data from a transgender female competitive cyclist

    by Blair R. Hamilton, Ke Hu, Fergus Guppy, Yannis Pitsiladis

    Background and Aims: The Union Cycliste Internationale has deemed transgender female athlete’s ineligible for the female category due to concerns about performance advantages. We conducted a follow-up analysis on laboratory-based performance indicators of sports performance using data from a longitudinally assessed transgender woman athlete undergoing gender-affirming hormone therapy (GAHT). Methods: We evaluated laboratory performance indicators in transgender and cisgender women athletes using dual-energy X-ray absorptiometry scanning, handgrip strength measurement, jump testing, and cardiopulmonary exercise. Additionally, we assessed a transgender sub-elite cyclist before and after undergoing GAHT. Results: After one year of GAHT, the transgender athlete showed declines in handgrip strength (7–13 %), countermovement jump (23–29 %), and V̇O2max (15–30 %). After 3 months, several performance indicators (absolute handgrip, peak power, relative peak power, average power, relative average power, V̇O2max and relative V̇O2max) were above the mean of cisgender female athletes, while others (Relative handgrip, countermovement jump and relative countermovement jump) were below. Similar trends were observed at 6 months and 1 year. Summary: This hypothetical analysis, although with limited evidence, suggests the transgender athlete could compete equitably in elite cycling events within the female category after one year of GAHT. Adjustments based on competition data would ensure fairness. Further analysis after an additional 12 months is recommended to assess the impact of 2 years of GAHT. An outright ineligibility for the female category for transgender women athletes would hinder a true assessment of performance fairness.